Methods for accelerated return of skin integrity and for the treatment of impetigo
Methods of treatment and dosage regimes using hydrophobic gel or foam compositions comprising a tetracycline antibiotic for accelerating the return of skin integrity and or in treating or alleviating a disorder including impetigo, acne, rosacea, a skin disease caused by a bacteria or a tetracycline antibiotic responsive disease, wherein the foam composition or gel is administered topically to a target area on a subject having the disorder and wherein the target area comprises an area of skin, or mucosa or an eye.
1. A method of treating or alleviating impetigo comprising topically administering an effective amount of a tetracycline antibiotic foam to a target area on a mammal in need thereof, wherein the target area comprises an area of skin or mucosa, and wherein the tetracycline antibiotic foam is produced from a foamable composition comprising:
(a) 60% to 90% by weight of at least one hydrophobic oil;
(b) a wax selected from the group consisting of a beeswax, a hydrogenated castor oil, a paraffin wax, a plant wax, an animal wax, a polyethylene wax, and a mixture of two or more thereof;
(c) at least one solid fatty alcohol having a carbon chain length of 14 to 22 carbons;
(d) optionally at least one solid fatty acid having a carbon chain length of 12 to 28 carbons;
(e) a tetracycline antibiotic selected from the group consisting of tetracycline, oxytetracycline, demeclocycline, doxycycline, lymecycline, meclocycline, methacycline, minocycline, rolitetracycline, chlorotetracycline, tigecycline, and a mixture of two or more thereof; and
(f) a liquefied or compressed gas propellant; and
wherein the foamable composition does not comprise a surfactant.
2. The method of claim 1 , wherein the concentration of the liquefied or compressed gas propellant is 3% to 25% by weight of the foamable composition.
3. The method of claim 1 , wherein the wax is selected from the group consisting of a beeswax, a hydrogenated castor oil, and a mixture thereof.
4. The method of claim 1 , wherein the tetracycline antibiotic is present in a free base form, a salt form, a hydrate form, or a complex form.
5. The method of claim 4 , wherein the tetracycline antibiotic is minocycline hydrochloride, and wherein the concentration of minocycline hydrochloride is 0.2% to 10% by weight of the foamable composition.
6. The method of claim 4 , wherein the tetracycline antibiotic is doxycycline hyclate, and wherein the concentration of doxycycline hyclate is 0.2% to 10% by weight of the foamable composition.
7. The method of claim 1 , wherein the tetracycline antibiotic foam is administered twice daily.
8. The method of claim 1 , wherein the hydrophobic oil is selected from the group consisting of a mineral oil, a soybean oil, a coconut oil, cyclomethicone, and a mixture of two or more thereof.
9. The method of claim 1 , wherein the at least one solid fatty alcohol is selected from the group consisting of myristyl alcohol, cetostearyl alcohol, stearyl alcohol, behenyl alcohol, and a mixture of two or more thereof.
10. The method of claim 1 , wherein the foamable composition does comprise the optional at least one solid fatty acid having a carbon chain length of 12 to 28 carbons.
11. The method of claim 10 , wherein the least one solid fatty acid having a carbon chain length of 12 to 28 carbons is stearic acid.
12. The method of claim 1 , wherein the foamable composition further comprises fumed silica.
13. The method of claim 1 , wherein the mammal is a human.
14. The method of claim 1 , wherein tetracycline antibiotic foam is administered at least once daily.
15. The method of claim 1 , wherein the tetracycline antibiotic is micronized.
16. The method of claim 1 , wherein the concentration of tetracycline antibiotic is 0.2 to 10% by weight of the foamable composition.